Adenovirus gene therapy vehicle and cell line
AssigneeThe Trustees of the University of Pennsylvania
InventorsGuang-Ping Gao, James M. Wilson
Life of this patent
Estimating the term…
Abstract
A novel adenovirus E1/E4 expressing packaging cell line is provided, which permits the generation of recombinant adenoviruses deleted in both gene regions. The E1/E4 deleted recombinant adenovirus is capable of expressing a selected transgene product in cells in vivo or in vitro. This recombinant virus is useful in the treatment of genetic disorders.
Claims8
The cell line 293-10-3 ATCC Accession No. PTA-2361.
A method for producing a recombinant adenovirus deleted in the E1 and E4 genes, comprising the step of:
- introducing to cell line 293-10-3 ATCC Accession No. PTA-2361
- (i) a recombinant vector comprising adenovirus 5′ and 3′ cis elements necessary for replication and packaging flanking a transgene under the control of regulatory sequences that direct expression of said transgene in a host cell, and
- (ii) a helper virus providing any adenovirus genes not present in the cell line or in said vector, that are necessary to permit production of said recombinant adenovirus.
The cell line 293-27-18 ATCC Accession No. PTA-2511.
A method for producing a recombinant adenovirus deleted in the E1 and E4 genes, comprising the step of:
- introducing to cell line 293-27-18 ATCC Accession No. PTA-2511
- (i) a recombinant vector comprising adenovirus 5′ and 3′ cis elements necessary for replication and packaging flanking a transgene under the control of regulatory sequences that direct expression of said transgene in a host cell, and
- (ii) a helper virus providing any adenovirus genes not present in the cell line or in said vector, that are necessary to permit production of said recombinant adenovirus.
Dependencies are inferred from the claim text.